Litifilimab clinical trials
Also written BIIB059.
How each study uses litifilimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the litifilimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Studies
Open first, then newest update. How each study uses litifilimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)Enrolling by invitationPhase 3BiogenNCT05352919Written as Litifilimab
- A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus ErythematosusEnrolling by invitationPhase 3BiogenNCT06044337Written as BIIB059 (litifilimab)
- A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus ErythematosusActive, not recruitingPhase 2/3BiogenNCT05531565Written as Litifilimab
- A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus ErythematosusActive, not recruitingPhase 3BiogenNCT04895241Written as Litifilimab
- A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus ErythematosusActive, not recruitingPhase 3BiogenNCT04961567Written as Litifilimab
- Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)CompletedPhase 2BiogenNCT02847598Written as BIIB059 (litifilimab)
- Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 (Litifilimab) in Healthy Volunteers and Participants With Systemic Lupus ErythematosusCompletedPhase 1BiogenNCT02106897Written as BIIB059 (litifilimab)
- Safety, Tolerability, and Pharmacokinetics of Single Doses of BIIB059 in Healthy Japanese Subjects.CompletedPhase 1BiogenNCT03224793Written as BIIB059
Given beside what is tested · 1 — litifilimab is usual care or a partner of the new treatment
Codes
What other systems call litifilimab · ClinicalTrials.gg INT018187
- UNII (FDA) V27E9V3K7GLITIFILIMABOne source FDA
- NCI Thesaurus C186413LitifilimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | V27E9V3K7G | LITIFILIMAB | One source FDA |
| NCI Thesaurus | C186413 | Litifilimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.